The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer’s Disease Spectrum

0
119

    • Aalten P.
    • de Vugt M.E.
    • Jaspers N.
    • et al.

    The course of neuropsychiatric symptoms in dementia.

    Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry. 2005; 20: 523-530

    • Zhao Q.F.
    • Tan L.
    • Wang H.F.
    • et al.

    The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis.

    J Affect Disord. 2016; 190: 264-271

    • Donovan N.J.
    • Amariglio R.E.
    • Zoller A.S.
    • et al.

    Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease.

    Am J Geriatr Psychiatry. 2014; 22: 1642-1651

    • Monastero R.
    • Mangialasche F.
    • Camarda C.
    • et al.

    A systematic review of neuropsychiatric symptoms in mild cognitive impairment.

    J Alzheimers Dis. 2009; 18: 11-30

    • Ramakers I.H.G.B.
    • Verhey F.R.J.
    • Scheltens P.
    • et al.

    Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment.

    Psychol Med. 2013; 43: 911-920

    • Dam D.V.
    • Vermeiren Y.
    • Dekker A.D
    • et al.

    Neuropsychiatric disturbances in Alzheimer’s disease: what have we learned from neuropathological studies?.

    Cur Alzheimer Res. 2016; 13: 1145-1164

    • Shaw L.M.
    • Vanderstichele H.
    • Knapik-Czajka M.
    • et al.

    Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects.

    Ann Neurol. 2009; 65: 403-413

  • MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults.

    Neurology. 2012; 78: 84-90

    • Vemuri P.
    • Wiste H.
    • Weigand S.
    • et al.

    MRI and CSF biomarkers in normal, MCI, and AD subjects predicting future clinical change.

    Neurology. 2009; 73: 294-301

    • Barca M.L.
    • Persson K.
    • Eldholm R.
    • et al.

    Trajectories of depressive symptoms and their relationship to the progression of dementia.

    J Affect Disord. 2017; 222: 146-152

    • Kramberger M.G.
    • Jelic V.
    • Kåreholt I.
    • et al.

    Cerebrospinal fluid Alzheimer markers in depressed elderly subjects with and without Alzheimer’s disease.

    Dement Geriatr Cogn Dis Extra. 2012; 2: 48-56

    • Arnold S.E.
    • Xie S.X.
    • Leung Y.Y.
    • et al.

    Plasma biomarkers of depressive symptoms in older adults.

    Transl Psychiatry. 2012; 2: e65

    • Auning E.
    • Selnes P.
    • Grambaite R.
    • et al.

    Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment.

    Acta Psychiatr Scand. 2015; 131: 139-147

    • Engelborghs S.
    • Maertens K.
    • Vloeberghs E.
    • et al.

    Neuropsychological and behavioural correlates of CSF biomarkers in dementia.

    Neurochem Int. 2006; 48: 286-295

    • Kuo H.C.
    • Yen H.C.
    • Huang C.C.
    • et al.

    Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer’s disease.

    Int J Neurosci. 2015; 125: 747-754

    • Nathan P.J.
    • Lim Y.Y.
    • Abbott R.
    • et al.

    Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI).

    Neurobiol Aging. 2017; 53: 1-10

    • Skogseth R.
    • Mulugeta E.
    • Jones E.
    • et al.

    Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer’s disease.

    Dement Geriatr Cogn Dis. 2008; 25: 559-563

    • Peters M.E.
    • Lyketsos C.G.

    Beyond memory: a focus on the other neuropsychiatric symptoms of dementia.

    Am J Geriatr Psychiatry. 2015; 23: 115-118

    • Apostolova L.G.
    • Cummings J.L.

    Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature.

    Dement Geriatr Cogn Dis. 2008; 25: 115-126

    • Aalten P.
    • Ramakers I.H.
    • Biessels G.J.
    • et al.

    The Dutch Parelsnoer Institute-Neurodegenerative diseases; methods, design and baseline results.

    BMC Neurol. 2014; 14: 254

    • Folstein M.F.
    • Folstein S.E.
    • McHugh P.R.

    “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician.

    J Psychiatr Res. 1975; 12: 189-198

    • McKhann G.
    • Drachman D.
    • Folstein M.
    • et al.

    Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer’s disease.

    Neurology. 1984; 34: 939-944

  • Mild cognitive impairment as a diagnostic entity.

    J Intern Med. 2004; 256: 183-194

    • Cummings M.Mega
    • Gray K.
    • et al.

    The Neuropsychiatric Inventory comprehensive assessment of psychopathology in dementia.

    Neurology. 1994; 44: 2308

    • Kaufer D.I.
    • Cummings J.L.
    • Ketchel P.
    • et al.

    Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.

    J Neuropsychiatry Clin Neurosci. 2000; 12: 233-239

    • Geda Y.E.
    • Roberts R.O.
    • Knopman D.S.
    • et al.

    Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study.

    Arch Gen Psychiatry. 2008; 65: 1193-1198

    • Lyketsos C.G.
    • Lopez O.
    • Jones B.
    • et al.

    Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

    JAMA. 2002; 288: 1475-1483

    • Jack Jr., CR
    • Bernstein M.A.
    • Fox N.C.
    • et al.

    The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI methods.

    J Magn Reson Imaging. 2008; 27: 685-691

    • Bron E.E.
    • Steketee R.M.
    • Houston G.C.
    • et al.

    Diagnostic classification of arterial spin labeling and structural MRI in presenile early stage dementia.

    Hum Brain Mapp. 2014; 35: 4916-4931

    • Ashburner J.
    • Friston K.J.

    Unified segmentation.

    Neuroimage. 2005; 26: 839-851

  • Team R Core: A language and environment for statistical computing. 2016.

    • Chmura Kraemer H.
    • Kiernan M.
    • Essex M.
    • et al.

    How and why criteria defining moderators and mediators differ between the Baron & Kenny and MacArthur approaches.

    Health Psychol. 2008; 27: S101

    • Kraemer H.C.
    • Stice E.
    • Kazdin A.
    • et al.

    How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors.

    Am J Psychiatry. 2001; 158: 848-856

    • Ramakers I.H.
    • Verhey F.R.

    The difficult distinction between affective disorders and mild cognitive deterioration. Neuropsychiatric Symptoms of Cognitive Impairment and Dementia.

    Springer,
    2017: 11-26

    • Banning L
    • Ramakers I
    • Deckers K
    • et al.

    Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer’s disease: a systematic literature review.

    Neurosci Biobehav Rev. 2019; 107: 346-359

  • Depression and risk of developing dementia.

    Nat Rev Neurol. 2011; 7: 323-331

    • Kales H.C.
    • Gitlin L.N.
    • Lyketsos C.G.

    Assessment and management of behavioral and psychological symptoms of dementia.

    BMJ. 2015; 350: h369

  • Late-life anxiety and cognitive impairment: a review.

    Am J Geriatr Psychiatry. 2008; 16: 790-803

    • Tateno A.
    • Sakayori T.
    • Higuchi M.
    • et al.

    Amyloid imaging with [(18)F]florbetapir in geriatric depression: early-onset versus late-onset.

    Int J Geriatr Psychiatry. 2015; 30: 720-728

    • Lanctôt K.L.
    • Amatniek J.
    • Ancoli-Israel S.
    • et al.

    Neuropsychiatric signs and symptoms of Alzheimer’s disease: new treatment paradigms.

    Alzheimers Dement TRCI. 2017; 3: 440-449

  • Source link

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here